Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vildagliptin (LAF237) effects on gastric emptying and satiety in type 2 diabetes
NCT00952991Phase 3Completed
- Sponsor
- Mayo Clinic
- Start
- May 2005
- Primary completion
- Feb 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of vildagliptin in type 2 diabetes mellitus (T2DM), sponsored by Mayo Clinic. Started May 2005; status: completed.
02
Drugs
vildagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00952991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00952991.